Arbutus Biopharma Stock News

Arbutus Biopharma Corporation (NASDAQ: ABUS ) and Genevant have sued Moderna Inc (NASDAQ: MRNA ) for infringing on their patent on a lipid nanoparticle platform that they say was crucial to the delivery of Moderna’s widely-used COVID-19 vaccine. The companies are seeking an award of damages sufficient to compensate Arbutus and Genevant for Moderna’s infringement under 35 U.S.C. §284, in no event less than a reasonable royalty on all infringing sales or other dispositions of Accused Product. Moderna tried to preempt a lawsuit by asking federal courts to block certain Arbutus patents, but the U.S. Court of Appeals for the Full story available on Benzinga.com

NEW YORK , Feb. 28, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for REGI, FHN, INDO, ABUS, and FUV. … Full story available on Benzinga.com

The clinical-stage biopharma company Arbutus Biopharma (ABUS) and Genevant Sciences has filed a lawsuit on Monday against Moderna (MRNA) and an affiliate of the biotech seeking damages…

© Reuters. FILE PHOTO: Boxes containing the Moderna COVID-19 vaccine are prepared to be shipped at the McKesson distribution center in Olive Branch, Mississippi, U.S. December 20, 2020. Paul Sancya/Pool via REUTERS/File Photo (Reuters) – Arbutus Biopharma (NASDAQ:) Corp said on Monday it had filed a lawsuit against Moderna (NASDAQ:) Inc seeking damages for infringement …

Arbutus Biopharma Corp said on Monday it had filed a lawsuit against Moderna Inc seeking damages for infringement of patents related to its COVID-19 vaccine.

WARMINSTER, Pa., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, and Genevant Sciences today filed a lawsuit in the U.S. District Court for the District of Delaware against Moderna, Inc. (Nasdaq: MRNA) and a Moderna affiliate seeking damages for infringement of U.S. Patent Nos. 8,058,069, 8,492,359, 8,822,668, 9,364,435, 9,504,651, and 11,141,378 in the manufacture and sale of MRNA-1273, Moderna’s vaccine for COVID-19. The patents relate to nucleic acid-lipid particles and lipid vesicles, as well as compositions and methods for their use. The filed complaint is available on the Arbutus website .

VANCOUVER, British Columbia and CAMBRIDGE, Mass. and BASEL, Switzerland, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic acid delivery company, and Arbutus Biopharma Corporation (Nasdaq: ABUS) today filed a lawsuit in the U.S. District Court for the District of Delaware against Moderna, Inc. (Nasdaq: MRNA) and an affiliate seeking damages for infringement of U.S. Patent Nos. 8,058,069, 8,492,359, 8,822,668, 9,364,435, 9,504,651, and 11,141,378 in the manufacture and sale of mRNA-1273, Moderna’s vaccine for COVID-19. The patents relate to nucleic acid-lipid particles and lipid vesicles, as well as compositions and methods for their use. The filed complaint is available at https://investor.roivant.com/news-events/events .

Shares of Arbutus Biopharma Corp. ABUS, +7.21% gained 11.0% in premarket trading on Monday after the company said it is suing Moderna Inc. MRNA, +1.70% for infringing on several patents that relate to

Arbutus Biopharma Corp said on Monday it had filed a lawsuit against Moderna Inc seeking damages for infringement of patents related to its COVID-19 vaccine.

Penny stocks to buy for under $5 that have unusual options activity right now. The post 4 Penny Stocks To Buy For Under $5 With Unusual Options Activity appeared first on Penny Stocks to Buy, Picks, N

NEW YORK , Feb. 18, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CGNX, BLMN, LTHM, SAND, and ABUS. … Full story available on Benzinga.com

WARMINSTER, Pa., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that it has scheduled its fourth quarter and year end 2021 financial results and corporate update for Thursday, March 3, 2022. The schedule for the press release and conference call/webcast are as follows:

WARMINSTER, Pa., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel

Vir: Expansion Of Covid-19 Antiviral Drug And Hepatitis B Pipeline Makes It An Attractive Bet

The company could have great prospects if its hepatitis B virus therapy is successful in clinical testing.